Studies related to Hemoglobin and Ashwagandha

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Increase
Values g/dl. Placebo: before 12.7 (1.2), after 12.5 (1.2). 125 mg before 12.7 (1.2), after 13.5 (1.5). 250 mg before 12.6 (1.3), after 13.1 (1.4). 500 mg before 12.1 (1.2), after 13.2 (1.1)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."

Effects Of An Aqueous Extract Of Withania Somnifera On Strength Training Adaptations And Recovery: The STAR Trial

Effect Decrease
Values (g/dl). Placebo: before 15.4 ± 0.90, after 15.8 ± 0.94. Ashwagandha: before 15.5 ± 0.24, after 15.2 ± 0.53
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 40
Gender Male
Age Range 18-29, 30-44, 45-64
Body Types Obese, Overweight, Average
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 40 healthy young, recreationally active men were allocated to take 500 mg of a potent ashwagandha extract (standardized to 10% withanolides) or placebo for 12 weeks.

The primary outcome was the change in muscle strength as measured by one-repetition maximum with the Smith machine bench press and back squat. There was a statistically significant increase in 1-repetition max for both squat and bench press. While the ashwagandha group saw a greater improvement in 7.5 km running down, this wasn't statistically significant between groups and the same was the case for average and peak power for squats and bench press, and number of repetitions.

There were no statistically significant changes between groups for body fat percentage, lean mass, fat mass, Android/Gynoid Ratio, visceral fat, or body mass. There were no statistically significant differences between groups on subjective assessments on a visual analog scale for perceived recovery, invigoration, mood, desire to work out, willingness to train, optimism, or soreness.

For blood testing, a large number of things were measured but none of it is particularly noteworthy (available in the values box in each respective outcome).
Funding issues for this study:
"Funding for this study was provided by Natreon, Inc. (New Brunswick, NJ, USA) through a restricted grant. The sponsor of the study was not involved in the conduct, interpretation, or the preparation of the final manuscript. A blinded third-party audited the collected data for accuracy and performed the statistical analyses."